{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:12:23Z","timestamp":1777489943501,"version":"3.51.4"},"reference-count":63,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term data helps assess the consistency of efficacy, tolerability, and safety of acute treatment over repeated use for different attacks. Real-world studies help assess tolerability, safety, and efficacy in patients with possibly refractory chronic migraine, more comorbidities, other diseases such as cardiovascular diseases, and polypharmacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a narrative review of the long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine. Both manuscripts and abstracts were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The efficacy and tolerability of lasmiditan, ubrogepant, and rimegepant are maintained over time. No significant cardiovascular adverse events were thought to be related to any of these medications. The rare instances of palpitations and\/or tachycardia occurred within 48 hours of lasmiditan. One participant with a history of supraventricular tachycardia had sinus tachycardia thought to be related to ubrogepant which did not recur despite continued use. One case of thrombocytopenia and two cases of increased aspartate aminotransferase and alanine transaminase were thought to be possibly related, but the alanine transaminase and aspartate aminotransferase levels normalized despite continued use of ubrogepant. A case of first-degree atrioventricular block was considered possibly related to rimegepant. Acute use of rimegepant was associated with a decrease in monthly migraine days over time. The three medications were associated with improvement in function and\/or productivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Long-term and real-world data of tolerability, safety and efficacy of lasmiditan, ubrogepant, and rimegepant is thus far consistent with prior studies, but more longitudinal data that clarifies long-term safety as well as consistency and predictors of response is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024221137092","type":"journal-article","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T03:01:25Z","timestamp":1675566085000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks"],"prefix":"10.1177","volume":"43","author":[{"given":"Olivia","family":"Begasse de Dhaem","sequence":"first","affiliation":[{"name":"Hartford HealthCare, Neurology Department, University of Connecticut, Milford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W","family":"Dodick","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Phoenix, AZ, USA"},{"name":"Atria Institute, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,2,5]]},"reference":[{"key":"bibr1-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7516.572"},{"key":"bibr2-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.04.003"},{"key":"bibr3-03331024221137092","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730020-00001"},{"key":"bibr4-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-021-00322-8"},{"key":"bibr5-03331024221137092","unstructured":"FDA. Real-World Evidence, https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence (2022, accessed 18 May 2022)"},{"key":"bibr6-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129197"},{"key":"bibr7-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1177\/2515816320958176"},{"key":"bibr8-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70047-9"},{"key":"bibr9-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1111\/head.13510"},{"key":"bibr10-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398399"},{"key":"bibr11-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000771"},{"key":"bibr12-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1111\/head.13379"},{"key":"bibr13-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1159\/000116960"},{"key":"bibr14-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01088-4"},{"key":"bibr15-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419864132"},{"key":"bibr16-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.04.004"},{"key":"bibr17-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00185-5"},{"key":"bibr18-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1111\/head.13682"},{"key":"bibr19-03331024221137092","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1212\/WNL.96.15_supplement.2370","volume":"96","author":"Schim J","year":"2021","journal-title":"Neurology"},{"key":"bibr20-03331024221137092","doi-asserted-by":"crossref","unstructured":"Hutchinson S, Schim J, Lipton R, et\u00a0al. Oral rimegepant 75\u2009mg is safe and well tolerated in adults with migraine and cardiovascular risk factors: results of a multicenter, long-term, open-label safety study. American Academy of Neurology Abstract Website, https:\/\/index.mirasmart.com\/AAN2021\/PDFfiles\/AAN2021-001995.html (2021 accessed 10 January 2022)","DOI":"10.1212\/WNL.96.15_supplement.1995"},{"key":"bibr21-03331024221137092","doi-asserted-by":"crossref","unstructured":"Pavlovic JM, Ailani J, Hutchinson S, et al. Ubrogepant was safe and well tolerated in the acute treatment of perimenstrual migraine (1616).\n                      Neurology\n                      2021; 96: 1616.","DOI":"10.1212\/WNL.96.15_supplement.1616"},{"key":"bibr22-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1111\/head.14062"},{"key":"bibr23-03331024221137092","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1212\/WNL.96.15_supplement.2342","volume":"96","author":"Smith T","year":"2021","journal-title":"Neurology"},{"key":"bibr24-03331024221137092","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1212\/WNL.96.15_supplement.5072","volume":"96","author":"Kudrow D","year":"2021","journal-title":"Neurology"},{"key":"bibr25-03331024221137092","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1212\/WNL.96.15_supplement.5142","volume":"96","author":"Mullin K","year":"2021","journal-title":"Neurology"},{"key":"bibr26-03331024221137092","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1212\/WNL.96.15_supplement.4737","volume":"96","author":"L\u2019Italien G","year":"2021","journal-title":"Neurology"},{"key":"bibr27-03331024221137092","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1212\/WNL.96.15_supplement.5054","volume":"96","author":"Mullin K","year":"2021","journal-title":"Neurology"},{"key":"bibr28-03331024221137092","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1212\/WNL.96.15_supplement.4945","volume":"96","author":"L\u2019Italien G","year":"2021","journal-title":"Neurology"},{"key":"bibr29-03331024221137092","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1212\/WNL.96.15_supplement.5084","volume":"96","author":"Turner I","year":"2021","journal-title":"Neurology"},{"key":"bibr30-03331024221137092","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1212\/WNL.96.15_supplement.5029","volume":"96","author":"Turner I","year":"2021","journal-title":"Neurology"},{"key":"bibr31-03331024221137092","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.96.15_supplement.1811","volume":"96","author":"Vincent M","year":"2021","journal-title":"Neurology"},{"key":"bibr32-03331024221137092","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.98.18_supplement.1167","volume":"98","author":"Shewale AR","year":"2022","journal-title":"Neurology"},{"key":"bibr33-03331024221137092","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1212\/WNL.98.18_supplement.3177","volume":"98","author":"Adams AM","year":"2022","journal-title":"Neurology"},{"key":"bibr34-03331024221137092","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1212\/WNL.98.18_supplement.1192","volume":"98","author":"Iaconangelo C","year":"2022","journal-title":"Neurology"},{"key":"bibr35-03331024221137092","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1212\/WNL.98.18_supplement.873","volume":"98","author":"Jensen C","year":"2022","journal-title":"Neurology"},{"key":"bibr36-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211034005"},{"key":"bibr37-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1111\/head.13854"},{"key":"bibr38-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1111\/head.14130"},{"key":"bibr39-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1903846"},{"key":"bibr40-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"bibr41-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"bibr42-03331024221137092","doi-asserted-by":"crossref","DOI":"10.1111\/head.14056","volume":"61","author":"Schwedt TJ","year":"2021","journal-title":"Headache"},{"key":"bibr43-03331024221137092","unstructured":"Rosen N, Mathew PG, Buchanan A, et\u00a0al. Long-term cardiovascular safety of lasmiditan for the acute treatment of migraine for up to one year: interim results of an open-label phase 3 study (GLADIATOR). Headache 2020; 60. doi\/10.1111\/head.13854"},{"key":"bibr44-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"bibr45-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"bibr46-03331024221137092","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1212\/WNL.94.15_supplement.4726","volume":"94","author":"Lipton R","year":"2020","journal-title":"Neurology"},{"key":"bibr47-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1111\/head.13930"},{"key":"bibr48-03331024221137092","unstructured":"Lipton R, Berman G, Kudrow D, et\u00a0al. Long-term, open-label safety study of rimegepant 75\u2009mg for the treatment of migraine (study 201): interim analysis of safety and exploratory efficacy, https:\/\/www.biohavenpharma.com\/sites\/default\/files\/documents\/rimegepant-long-term-safety-201-2019-ahs.pdf (2019, accessed 14 May 2022)."},{"key":"bibr49-03331024221137092","doi-asserted-by":"crossref","DOI":"10.1177\/25158163221075596","volume":"5","author":"L\u2019Italien G","year":"2022","journal-title":"Cephalalgia Reports"},{"key":"bibr50-03331024221137092","unstructured":"Baskin S, Buse D, Jensen C, et\u00a0al. Rimegepant 75\u2009mg is safe and well tolerated for the acute treatment of migraine in adults using selective serotonin reuptake inhibitors and other antidepressants: results from a long-term open-label safety study (Study 201), https:\/\/www.biohavenpharma.com\/sites\/default\/files\/2020-05\/ahs-2020-rimegepant-long-term-safety-with-ssris-antidepressants.pdf (2020, accessed 14 May 2022)."},{"key":"bibr51-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01897-2"},{"key":"bibr52-03331024221137092","volume":"61","author":"Croop R","year":"2021","journal-title":"Headache"},{"key":"bibr53-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.5144"},{"key":"bibr54-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"bibr55-03331024221137092","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1212\/WNL.94.15_supplement.1864","volume":"94","author":"L\u2019Italien G","year":"2020","journal-title":"Neurology"},{"key":"bibr56-03331024221137092","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1212\/WNL.96.15_supplement.4704","volume":"96","author":"Johnston K","year":"2021","journal-title":"Neurology"},{"key":"bibr57-03331024221137092","volume":"61","author":"Schobel V.","year":"2021","journal-title":"Headache"},{"key":"bibr58-03331024221137092","doi-asserted-by":"crossref","DOI":"10.1111\/head.14054","volume":"61","author":"Pohl G","year":"2021","journal-title":"Headache"},{"key":"bibr59-03331024221137092","volume":"61","author":"Johnston K","year":"2021","journal-title":"Headache"},{"key":"bibr60-03331024221137092","volume":"61","author":"Ju S","year":"2021","journal-title":"Headache"},{"key":"bibr61-03331024221137092","unstructured":"FDA. Drug Safety-related Labeling Changes (SrLC), https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm?event=searchdetail.page&DrugNameID=1894 (accessed 31 July 2022)."},{"key":"bibr62-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"bibr64-03331024221137092","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024221137092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024221137092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024221137092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:45:31Z","timestamp":1777387531000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024221137092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1177\/03331024221137092"],"URL":"https:\/\/doi.org\/10.1177\/03331024221137092","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"article-number":"03331024221137092"}}